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Abstract
Influenza virus produces a protein, NS1, that inhibits infected cells from releasing type I interferon (IFN) and blocks
maturation of conventional dendritic cells (DCs). As a result, influenza virus is a poor activator of both mouse and human
DCs in vitro. However, in vivo a strong immune response to virus infection is generated in both species, suggesting that
other factors may contribute to the maturation of DCs in vivo. It is likely that the environment in which a DC encounters a
virus would contain multiple pro-inflammatory molecules, including type I IFN. Type I IFN is a critical component of the viral
immune response that initiates an antiviral state in cells, primarily by triggering a broad transcriptional program that
interferes with the ability of virus to establish infection in the cell. In this study, we have examined the activation profiles of
both conventional and plasmacytoid dendritic cells (cDCs and pDCs) in response to an influenza virus infection in the
context of a type I IFN-containing environment. We found that both cDCs and pDCs demonstrate a greater activation
response to influenza virus when pre-exposed to IFN-b (IFN priming); although, the priming kinetics are different in these
two cell types. This strongly suggests that type I IFN functions not only to reduce viral replication in these immune cells, but
also to promote greater DC activation during influenza virus infections.
Citation: Phipps-Yonas H, Seto J, Sealfon SC, Moran TM, Fernandez-Sesma A (2008) Interferon-b Pretreatment of Conventional and Plasmacytoid Human
Dendritic Cells Enhances Their Activation by Influenza Virus. PLoS Pathog 4(10): e1000193. doi:10.1371/journal.ppat.1000193
Editor: Marco Colonna, Washington University in Saint Louis School of Medicine, United States of America
Received February 5, 2008; Accepted October 2, 2008; Published October 31, 2008
Copyright:  2008 Phipps-Yonas et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by NIH grant U19 AI62623, NIH contract HHSN266200500021C, and NIH grant RO1 AI041111.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: thomas.moran@mssm.edu (TMM); ana.sesma@mssm.edu (AF-S)
Introduction
Dendritic cells (DCs) play a key role in the initiation and
regulation of the immune system. They respond to various
microbial stimuli by undergoing a process of activation that
propels them to migrate to draining lymph nodes and endows
them with the ability to efficiently activate T cells [1,2]. The
process of DC activation involves several steps including
upregulation of surface markers, cytokine and chemokine secretion
and the ability to leave the tissue and migrate to draining lymph
nodes, and is also known as DC maturation. Depending on the
nature of the stimulus maturation is signified by the up-regulation
of MHC and co-stimulatory molecules, as well as the secretion of
some mixture of cytokines and chemokines that may include type I
interferons (IFN-a and IFN-b), IL-6, IL-12, TNF-a, IL-8, IP-10,
RANTES and MIP-1b [2,3].
In response to a viral infection, DCs can be activated by two
separate pathways: a toll like receptor (TLR)-dependent and a
TLR-independent pathway. The TLR-dependent pathway is
made up of several different TLRs that bind specific pathogen-
associated-molecular-patterns (PAMPs). TLR 3, 7/8 and 9 are the
sensors for viral PAMPs recognizing double-stranded RNA
(dsRNA), single-stranded RNA (ssRNA) and CpG DNA motifs,
respectively [4]. These TLRs are localized to the endosome and
signal via adaptor proteins to induce DC activation [5]. The TLR-
independent or internal pathway primarily consists of retinoic
acid-inducible gene-I (RIG-I) protein and melanoma differentia-
tion-associated gene product (MDA-5) both located in the
cytoplasm (RIG-I like receptors or RLR). RIG-I recognizes
cytoplasmic uncapped 59- tri-phosphate RNAs and MDA-5
recognizes cytoplasmic dsRNA [6].
Conventional DCs (cDCs) are considered the prototypic DCs as
they are proficient at presenting antigens and activating T cells [2].
The internal pathway has been shown to play a more significant
role in the activation of cDCs to RNA viruses than the TLR-
dependent pathway [7,8]. Plasmacytoid DCs are a second subset
of circulating human DCs, that in contrast to cDCs, use the TLR-
dependent pathways, specifically TLR7 and TLR9, for activation
in response to viruses [7,9].
Type I IFN is a critical component of the viral immune
response. Its expression is highly regulated and pDCs serve as the
primary producers of type I IFN in the body [10]. However,
virtually all nucleated cells are capable of producing IFN and
possess the IFN receptor, endowing them with the ability to
respond to type I IFN [11,12]. Type I IFN initiates an antiviral
state by stimulating the transcription of over 200 IFN-responsive
genes, some of which code for proteins that interfere with the
ability of viruses to establish infection in the cell [13]. Important
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among others [13,14]. Demonstrating the in vivo importance of
the type I IFN response is the observation that most successful
viruses contain IFN antagonists which act to suppress the IFN
pathway either at the level of IFN expression, IFN signaling or the
antiviral effects of IFN-responsive proteins [15].
Influenza virus contains a potent IFN antagonist, the NS1
protein, which efficiently blocks type I IFN release from infected
cells, including cDCs [16,17,18,19,20]. Moreover, the NS1 of
influenza virus has been shown to block virus triggered activation
of cDCs in vitro resulting in poor T cell stimulation [16,17]. These
observations are in contrast to those observed in vivo where fully
mature cDCs can be identified in the draining lymph nodes of
infected mice and a potent and protective immune response is
generated [21]. Thus, in vivo other factors are contributing to the
maturation of influenza infected DCs [22,23]. The most likely
factor contributing to the enhancement of DC maturation in vivo
is type I IFN [23,24].
Supporting this hypothesis, Pollara et. al. demonstrated type I
IFN can prime cDCs to overcome a viral blockade produced
during Herpes Simplex Virus (HSV) infections and Osterlund et.
al. reported that pre-treating cDCs with IFN-a enhanced influenza
A virus induced expression of TNF-a, IFN-a, IFN-b and IL-29
genes [23,25]. Furthermore, mouse DCs have been shown to
require type I IFN signaling in order to fully mature following
infection with Newcastle disease virus (NDV) and murine
cytomegalovirus (MCMV) [26,27,28] . Thus in addition to its
antiviral effects, type I IFN may also function as an enhancer of
DC maturation and may explain the discrepancy observed
between the in vitro and in vivo response of cDCs to influenza
virus infection. In this study, we systematically examined the
influence of type I IFN on the activation profile of cDCs and pDCs
in response to an influenza virus infection. We found that cDCs
demonstrate a greater activation response to influenza virus when
pre-exposed to IFN-b (IFN priming). Additionally, pretreatment of
pDCs with IFN augments their ability to release cytokines
although the priming kinetics of the two DC types differs
significantly. This strongly suggests that type I IFN functions not
only to reduce viral replication in cells but promote greater DC
activation during influenza virus infections.
Results
Impact of IFN dose and pre-exposure time on virus
replication
Type I IFN initiates an antiviral state in cells and inhibits viral
replication [15,29]. However, viruses differ in their sensitivity to
the antiviral effects of IFN [30]. To examine the effects of type I
IFN on the ability of human DCs to be infected by influenza virus,
we performed a dose and time titration of IFN-b exposure in GM-
CSF+IL-4 monocyte-derived DCs (hereafter referred to as
‘cDCs’). Figure 1 shows the impact of treatment with IFN-b on
the replication of influenza virus as measured by qRT-PCR of
influenza PR8 (PR8) viral product, NP protein. The results are
expressed as the percent of the copy number for the NP gene
relative to cells infected without IFN treatment. The cells were
pretreated for 2, 3, 6, 12, or 24 hours with the indicated amount of
IFN, after which the IFN was removed and the cells infected with
virus. Virus replication was measured by qRT-PCR at 12 hours
post infection (p.i.). Only pretreatment for 24 hours with the
highest dose (5,000 units/ml) of IFN-b was able to completely
prevent virus replication in DCs. Using the lower dose of IFN-b
(50 units/ml) the impact on virus replication was relatively minor
when the pre-incubation time was less than 6 hours for both cDC
and pDC (Figure 1A and data not shown). Regardless of the length
of pretreatment, the low dose of IFN was unable to completely
inhibit virus replication. Figure 1B and 1C show the relative
sensitivity of cDCs and pDCs to a three hour pretreatment with
the indicated concentrations of IFN-b. The results demonstrate
that IFN pretreatment reduces the ability of influenza virus to
replicate but eliminates replication only with a high concentration
and long incubation time.
Kinetics of gene transcription following a three hour
pulse with IFN-b
After IFN-b treatment of human DCs we observed that genes
coding for antiviral proteins such as MxA, viral sensors such as
RIG-I, transcription factors like STAT1 and IRF7, and chemo-
kines like IP-10 are upregulated (Figure 2). In these experiments
cells were pretreated with the indicated concentration of IFN-b for
3 hours after which the cytokine was removed. MxA, STAT1 and
IRF7 remain activated for a prolonged period after IFN is
removed but mRNA for RIG-I and particularly IP-10 are quickly
extinguished when the cytokine is withdrawn. In contrast, most of
the other genes associated with DC maturation were not
significantly upregulated by IFN treatment including IFN-a,
IFN-b, IL-6, and MIP-1b (which was inhibited by IFN treatment).
Gene activation was monitored at the indicated time points over a
24 hour period. Thus, IFN-b pretreatment does not result in
global gene profile changes in DCs, but rather affects select genes
with varying activation kinetics.
Pretreatment with IFN-b primes DCs to respond more
efficiently to virus infection
cDCs infected with PR8 virus demonstrate a minimal activation
profile when compared to the profile observed after infection with
viruses such as NDV or Sendai virus [17,31]. However, cDCs that
have been pretreated with a low dose of IFN-b for 3 hours prior to
PR8 virus infection demonstrate a substantial increase in mRNA
expression for numerous DC activation genes (Figure 3A). Viral
RNA expression was moderately decreased in IFN pretreated
Author Summary
Influenza infection leads to a serious respiratory infection
of the lung epithelium. Lying directly below the epithelial
cells are immune system sentinels known as dendritic cells.
These cells interact with the virus and carry parts of the
virus to draining lymph nodes to activate killer T cells. In
order to effectively carry out this function, DCs must
perceive the presence of a virus using receptors specially
adapted for this function. However, when DCs are mixed
with influenza virus in the laboratory, no activation occurs
because the virus produces a protein called NS1 that
blocks the receptors. Yet, patients infected with influenza
virus develop a strong adaptive response that leads to
recovery from infection. This observation suggests that
additional factors must be present that contribute to the
activation of the DCs. The most likely contributor is type I
interferon, a ubiquitous protein released from many cells
upon exposure to virus. In this study, we mixed influenza
virus with DCs in the presence of type I interferon and
found that this greatly enhanced their activation. Treat-
ment with interferon allowed the DC to bypass the block
in activation mediated by the influenza NS1 protein. Our
data suggest that the production of type I interferon
within an infected patient may endow the DCs with the
ability to fully respond to influenza virus.
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substantial increases above the level from IFN-b alone following
infection with PR8 virus. Moreover, genes not activated by IFN
showed enhanced activation following the three hour pretreatment
of IFN-b and PR8 virus infection (Figure 3A). This priming effect
was not limited to transcription since protein release was
equivalently increased (Figure 3B).
In contrast to cDCs, pDCs are highly activated by PR8 virus
infection (Figure 3C). Despite the increased basal level of pDC
activation following exposure to PR8 virus, pDCs were further
Figure 1. Impact of IFN dose and pre-exposure time on virus replication. (A) cDCs were incubated with IFN-b (50 or 5,000 units/ml) for time
indicated. Following pretreatment, the media was removed and fresh media was added along with PR8 virus for a 12-hour infection. (B) cDCs were
pretreated for 3 hours with between 5 and 5,000 units/ml IFN-b before a 12-hour infection with fresh media. (C) pDCs were pretreated for 3 hours
with between 5 and 5,000 units/ml IFN-b before 8-hour infection with fresh media. (A–C) All results are depicted as percent control, which is the ratio
of mRNA copy number of the influenza virus gene NP from samples infected with virus pretreated with IFN-b compared to cells without
pretreatment. Mean of samples is depicted with error bars representing the standard deviation of each sample. Data are representative of at least
three independent experiments.
doi:10.1371/journal.ppat.1000193.g001
Figure 2. Kinetics of gene transcription following a three hour IFN-b pulse. After 3 hours pretreatment of cDCs with IFN-b (0, 50, 500, or
5,000 units/ml), IFN media was removed and fresh media was added. mRNA expression profiles were determined at 0.5, 1, 3, 6, 12, and 24 hours after
IFN addition. IFN removal occurred at 0 hour. Standard deviation of each sample is depicted with data representative of at least two independent
experiments.
doi:10.1371/journal.ppat.1000193.g002
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and secrete more protein (Figure 3C and 3D). In conclusion, prior
exposure to IFN-b promotes stronger DC activation in both cDCs
and pDCs after infection by PR8 virus.
Impact of interferon treatment on cDC and pDC
following virus exposure
IFN-b pretreatment led to enhanced transcription and release of
proteins from both subpopulations of DCs following virus infection.
In order to determine whether exposure to IFN after virus infection
would have a similar effect, cDCs were infected with PR8 virus at
the 0 hour, and IFN-b (50 units/ml) was added at 0, 1.5, 3 and
6 hours post infection and left in the culture medium until the
mRNA expression profile of the treated cDCs was analyzed 8 hours
post infection. Specific viral RNA expression was inhibited by IFN-
b as shown in Figure 4 with the highest inhibition of viral NP gene
expression observed when IFN-b was added at the same time as the
virus. Despite this reduction in viral replication, cDC priming for
manygeneswasmostenhancedat0 hourspostinfection(Figure4A)
and decreased to basal levels from that point on. This priming effect
wasobserved for both IFN-a and IFN-b genes,aswell asgenes IFN-
responsive and IFN-independent (Figure 4A). Consistent with the
mRNA expression patterns, similar results were observed at the
protein level (Figure 4B).
When pDC were tested for priming by type I IFN after viral
infection, we observed a similar trend but smaller magnitude to
that seen with cDCs. Priming was minimally seen only at the early
time points for IFN-a and IP-10 and the effect diminished when
interferon was added at later time points (Figure 4C and 4D).
These data argue that the enhancing effect of IFN-b on DC
Figure 3. Pretreatment with IFN-b primes DCs to respond more efficiently to virus infection. (A,B) cDCs were pretreated with IFN-b
(50 units/ml) for 3 hours. Following pretreatment, the IFN media was removed and cells were infected with PR8 virus (IFN+PR8) for 12 hours.
Experiment was done in triplicate with error bars representing standard deviation between samples. All graphs have student t test p,0.05 between
the IFN+PR8 condition and other conditions, with the exception of MIP-1b with p.0.05. (C,D) pDCs were pretreated with IFN-b (50 units/ml) for
3 hours. Following pretreatment, the IFN media was removed and cells were infected with PR8 virus (IFN+PR8) for 12 hours. Control pDCs were either
infected only (PR8), pretreated with IFN only (IFN), or neither (NI). Mean of samples is depicted with error bars representing the standard deviation of
each sample. All graphs have student t test p,0.05 between the IFN+PR8 condition and other conditions. (A,C) Copy number of mRNA expression
values are depicted for the specific gene labeled. (B,D) Protein secretion amounts from multiplex ELISAs. Data are representative of at least 5
independent experiments.
doi:10.1371/journal.ppat.1000193.g003
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but decreases as time after infection increases.
Optimal DC priming is dependent on the time of IFN-b
exposure
In order to determine the optimal time of IFN-b pretreatment
needed to maximize DC activation, cDCs were pretreated with
IFN-b (50 units/ml) for several intervals between 24 and
0.5 hours, prior to a 12 hour PR8 virus infection. Pretreatment
with IFN-b for 1.5–6 hours led to optimal expression of DC
activation genes and proteins in cDCs (Figure 5A and 5B). Priming
occurred for IFN-a, IFN-b, IFN-responsive genes, and IFN-
independent genes (Figure 5A). Surprisingly, cDCs incubated in
IFN-b for 12 hours or longer became less responsive to the
priming effect as compared with the shorter time points
(Figure 5A). This may somewhat reflect the reduced replication
of the virus after the prolonged pretreatment.
Due to cell number limitations and cell viability issues; the time
course of pDC exposure to IFN-b was shortened (Figure 5C and
5D). Similar to the results seen in cDCs, virus replication was
inhibited best in cells exposed to IFN for the longest interval. As a
result of the shorter kinetics utilized with pDCs it is difficult to
ascertain precisely the optimum pretreatment time, however, it is
clear that pretreatment with IFN enhances the response of pDCs to
influenza virus infection over a broad time range. Protein secretion
from both cell types confirms the priming effects observed in RNA
expression in cDC and pDCs (Figure 5B and 5D).
IFN-b priming of DCs occurs throughout the course of
infection with different kinetics in cDCs and pDCs
DCs do not get productively infected with influenza virus
though the virus causes an abortive infection with viral message
synthesis peaking at between 6–8 hours [32]. To determine the
time points where the synergy between the viral and IFN
Figure 4. Effect of IFN treatment on cDC and pDC following virus exposure. (A,B) cDCs were infected with PR8 virus treated with IFN-b
(50 units/ml) at 0, 1.5, 3, and 6 hours p.i. After 8-hour infection, the supernatants were collected and RNA was isolated. (C,D) pDCs were infected with
PR8 virus treated with IFN-b (50 units/ml) at 0, 0.5, and 3 hours p.i. After 4-hour infection, the supernatants were collected and RNA was isolated.
Control DCs have only PR8 virus (PR8) or IFN added (IFN) or neither (NI). (A,C) Copy number of mRNA expression values are depicted for the specific
gene labeled. (B,D) Protein secretion amounts from multiplex ELISAs. Mean of samples are depicted with error bars of the standard deviation of each
sample. Data are representative of at least three independent experiments. Samples with student t test p,0.05 between the IFN+PR8 condition, and
the other conditions are marked with *.
doi:10.1371/journal.ppat.1000193.g004
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performed. cDCs, following a 3 hour pretreatment of IFN-b
(50 units/ml), were infected with PR8 virus and samples were
collected and analyzed for gene transcription and protein secretion
at time points beginning at 0 hours and ending at 10 hours
(Figure 6A). Viral mRNA levels show that the peak of viral
replication occurs between 6 and 8 hours but were reduced in the
IFN treated cells at all time points. Early stimulation of
transcription can be observed for the IFN responsive genes but
they are not enhanced by simultaneous infection at early time
points. However beginning at 4–6 hours after infection the
synergistic effect of IFN and infection is seen and correlates with
maximal viral gene transcription (Figure 6A).
Due to pDC cell number limitations, the time course of
infection for pDCs was shortened (Figure 6B and 6D). Similar to
the RNA expression trends in cDCs, viral replication was reduced
at all time points assayed in IFN+PR8 samples as compared to
PR8 samples. In contrast to cDCs, the synergistic effect of virus
and IFN treatment was observed earlier with pDC than with
cDCs. This was true with both IFN-responsive and IFN-
independent genes. The different kinetics observed with concom-
itant IFN treatment and infection most likely reflects different
activation mechanisms used by the DC subtypes. pDC can be
activated through a TLRs mechanism independent of virus
replication, while cDCs signal by the virus replication dependent
RLR pathway.
Figure 5. Kinetics of IFN-b priming. (A,B) cDCs were pretreated with IFN-b (50 units/ml) for 24, 12, 6, 3, 1, and 0.5 hours prior to 12-hour infection
with PR8 virus in fresh media. (C,D) pDCs were pretreated with IFN-b (50 units/ml) for 24, 12, 6, 3, 1, and 0.5 hours prior to 4-hour infection with PR8
virus in fresh media. Control DCs have only PR8 virus infection (PR8) or IFN pretreatment (IFN) or neither (NI). (A,C) Copy number of mRNA expression
values are depicted for the specific gene labeled. (B,D) Protein secretion amounts from multiplex ELISAs. Mean of samples are depicted with error
bars of the standard deviation of each sample. Data are representative of at least three independent experiments. Samples with student t test p,0.05
between the IFN+PR8 condition, and the other conditions are marked with *.
doi:10.1371/journal.ppat.1000193.g005
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secretion (Figure 6C and 6D). Regardless of the protein type, all
cytokines and chemokines tested demonstrated an increase in
secretion levels with time (Figure 6C and 6D).
pDC but not cDCs exposed to a low dose of IFN-b prior
to TLR ligand activation demonstrate DC activation
priming
To determine if the IFN-b priming was unique to live virus
responses, the robustness of priming was compared between live
influenza virus and several TLR ligands; in cDCs UV-inactivated
virus, poly (I:C) (TLR 3 ligand), CL-075 (TLR 7/8 ligand), and LPS
(TLR 4 ligand) were used and in pDCs Gardiquimod (TLR 7 ligand),
CpG, (TLR 9 ligand) and UV-inactivated PR8 virus were used. The
DCs were pretreated for 3 hours with the low dose of IFN-b
(50 units/ml) and treated with TLR ligands for between 0–12 hours.
For each ligand, both dose and time courses were performed and the
time point with the greatest priming (the largest differences between
samples treated with IFN-b and TLR ligand compared to the other
conditions) was determined. Table 1 represents the robustness of
priming, as determined by the fold increase of mRNA expression of
IFN+TLR ligand over the amount of expression from the IFN alone
sample and TLR alone samples [IFN+TLR ligand sample / (IFN
alone sample+TLR alone sample)] (Table 1, top part). Contrary to
the significant IFN-b priming observed when cDCs were infected
with live virus, only small differences were seen in cDCs mRNA
expression or protein secretion levels (data not shown) regardless of
exposure to IFN-b prior to TLR ligand addition (Table 1, top part).
This demonstrates that IFN-b priming in cDCs may be unique to live
virus and or activation by RLRs.
In contrast to the cDCs, pDCs demonstrated significant priming
with the TLR 7 ligand, Gardiquimod (Gard) for most genes
Figure 6. Kinetics of gene activation following IFN-b priming in cDCs and pDCs. (A,B) cDCs were pretreated with IFN-b (50 units/ml)
3 hours prior to infection with PR8 virus in fresh media. Infection was stopped at 0, 2, 4, 6, 8, and 10 hours p.i. Control cDCs have only PR8 virus
infection (PR8) or IFN pretreatment (IFN) or neither (NI). (C,D) pDCs were pretreated with IFN-b (50 units/ml) 3 hours prior to infection with PR8 virus
in fresh media. Infection was stopped at 0, 2, 4, and 6 hours p.i. Control pDCs have either PR8 virus infection (PR8) or IFN pretreatment (IFN) or neither
(NI). (A,C) Copy number of mRNA expression values are depicted for the specific gene labeled. (B,D) Protein secretion amounts from multiplex ELISAs.
Mean of samples are depicted with error bars of the standard deviation of each sample. Data are representative of at least three independent
experiments.
doi:10.1371/journal.ppat.1000193.g006
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CpG DNA (Table 1, bottom part, and Figure S1). The priming of
pDCs with TLR 7 ligand is consistent with TLR 7 being the
primary influenza viral sensor in the cell [7,9]. This increase in
mRNA expression was consistent with protein secretion levels
(Figure S1 and data not shown).
Overall, these data suggest that there are differences between
type I IFN priming in the DC subsets that follow with their
pathways of viral activation. In cDCs, activation by TLR agonist is
not significantly enhanced by IFN pretreatment, while in pDCs,
substantial enhancement is seen with the appropriate TLR ligand.
IFN priming allows cDCs to partially overcome inhibition
by IFN antagonist protein of the influenza virus
IFN priming clearly enhances cDC activation suggesting that it
may play an important role in the initiation of immunity. This
function could likely be used to overcome viral immune inhibitors
such as the NS1 protein from influenza virus that has been
demonstrated to inhibit cytokine secretion and maturation in both
mouse and human DCs. Therefore, we compared activation of
cDCs by NS1 deficient PR8 virus (DNS1) to DCs infected with
PR8 virus after a 3 hour pretreatment with 50–5,000 units/ml of
IFN-b. Figure 7 demonstrates cDCs primed with IFN respond to
wild type influenza virus at intensities comparable to an influenza
virus lacking the IFN antagonist (DNS1). IFN priming can rescue
the response to influenza for all cytokines and chemokines tested
with the exception of IFN-b and TNF-a (Figure 7). These genes
never reached the levels of DNS1 at any time point tested (0–
12 hours) after 3-hour IFN-b pretreatment (data not shown). This
may reflect differences in expression requirements for these
proteins. Our data indicate that the priming effects of IFN-b
counteract the inhibitory effects on DC activation genes induced
by the influenza virus NS1 protein. Interestingly, IFN-b and TNF-
a were still inhibited in the presence of the NS1 protein even when
DCs were pretreated by IFN-b. While the transcription of both
IFN-b and TNF-a is strongly dependent on NF-kb activation
other genes that are not so strongly dependent on this transcription
factor can be induced by IFN-b treatment even in the presence of
the influenza virus protein NS1 [19,33].
Discussion
Type I IFN has broad antiviral, immunological effects. It has
been shown to impact NK and cytotoxic T cell elimination of
virally infected cells, DC cross-presentation of viral antigens and B
cell antibody production and isotype switching [34,35]. Addition-
ally, IFN-a/b has been found to alter pDC migration, develop-
ment and maturation [36,37,38,39]. However, the impact of IFN-
b pretreatment on human DC activation by influenza virus
infection had not been fully explored.
Osterlund and colleagues initially described an effect of IFN
priming on DC responses to influenza virus [25]. In their studies
they showed that pretreatment with IFN could enhance mRNA
for type I and type III IFN and TNF [25]. These experiments
were performed using high MOI of virus and did not show
secreted protein data, leaving open the question of physiological
relevance. In the current work, we have comprehensively
examined the impact of type I IFN on the activation profiles
of both subpopulations of DCs in the context of influenza virus
infections and we demonstrate that IFN-b can potently enhance
their response to virus induced activation in a dose and time
dependent manner. Our data show that the priming effects of
type I IFN on DCs impact both the levels of mRNA expression
of IFN-responsive genes and the degree of viral replication. At
all concentrations and time points explored, the low dose of
IFN-b was able to impair viral replication but not able to
completely eliminate this replication in DCs. This incomplete
shut off may be necessary to allow DCs to be activated by the
viral infection.
The novel question explored here was how DCs would respond
to an influenza virus infection when they had been also exposed to
type I IFN. In the context of a virus infection in vivo, it is very
likely that epithelial cells may secrete type I IFN that can reach
underlying DCs before the virus does. If the antiviral state had
been initiated prior to or post infection, would DCs be activated by
the viral infection or would the antiviral state block viral DC
activation? Our results clearly demonstrate that both DC subsets
are not only not impaired in their response to virus infection after
exposure to type I IFN, but are primed by IFN-b, having increased
activation following infection with an influenza virus.
Table 1. pDCs but not cDCs exposed to a low dose of IFN-b prior to TLR ligand activation demonstrate DC activation priming.
cDCs IFN-a IFN-b TNF-a IL-6 IP-10 MIP-1b RANTES RIG-I MXA
PR8 28.45 13.61 7.13 8.64 37.72 9.66 n/d 7.14 12.88
PR8-UV 0.00 0.00 0.64 0.59 2.16 0.44 0.75 0.92 1.97
poly I:C 0.90 2.12 1.08 1.20 1.58 0.73 0.56 0.63 0.85
CL-075 0.00 0.00 3.01 4.06 0.17 0.80 3.28 1.42 1.82
LPS 0.53 1.75 2.10 0.51 0.84 0.91 0.69 0.37 0.56
pDCs IFN-a IFN-b TNF-a IL-6 IP-10 MIP-1b RANTES IRF7 MXA
PR8 5.18 3.38 1.22 1.73 1.32 4.45 3.32 0.65 0.94
PR8-UV 1.44 1.57 1.07 0.00 0.60 1.09 1.57 0.87 0.21
CpG 1.69 1.31 1.15 2.20 0.92 0.71 0.99 0.40 0.70
Gard. 4.91 2.62 1.78 1.73 0.06 0.87 2.25 1.55 1.17
cDCs and pDCs were pretreated with IFN-b (50 units/ml) 3 hours prior to treatment with live influenza PR8 virus, or UV-inactivated influenza, or LPS, or CpG, or poly (I:C),
or CL-075 Gardiquimod (Gard). The robustness of priming is given as the fold increase of mRNA expression of IFN+TLR ligand over the amount of expression from the
IFN alone sample and TLR alone samples [IFN+TLR ligand sample / (IFN alone sample+TLR alone sample)]. Data are representative of at least two independent
experiments in which both dose and time courses of activation were done. n/d signifies not determined.
doi:10.1371/journal.ppat.1000193.t001
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in vitro is in contradiction to the immunological outcome of
natural infection in vivo, since both humans and mice generate
strong adaptive immunity and are able to clear influenza virus
infection. Thus, DC activation must occur in vivo. Our data
suggest that IFN priming may account for the ability of a host to
respond to an infection that does not appear to elicit DCs
activation in vitro. IFN priming could be a mechanism for the host
to overcome the powerful ability of IFN antagonists such as the
influenza NS1 protein to block IFN production, signaling and/or
IFN-responsive genes actions. This has broad implications for the
role of DC activation in the context of an antiviral immunological
response. As shown by our data, very little viral replication is
needed to elicit strong DC activation. This is in sharp contrast to
cDC activation from viral infection in the absence of type I IFN,
which is weak and viral dose dependent.
Our results suggest that pDCs also benefit from IFN signaling.
Type I IFN has previously been shown to influence pDCs
development [36], while in our studies we demonstrate that IFN
has a substantial impact on the activation of pDCs following
influenza virus infection. The importance of pDC activation,
similar to the results of cDCs, is that despite very little viral input
and replication, pDCs respond fully. This ability of pDCs to
produce such large amounts of type I IFN with such small viral
input, may be reflective of the role of pDCs during a natural
infection. PDCs may be a host equivalent to IFN primed cDCs, in
the sense that pDCs are not sensitive to the inhibitory effects of
influenza virus IFN antagonist, the NS1 protein.
Despite the many similarities in IFN-b priming between the two
subtypes of DCs, there were several important differences. cDCs
demonstrated later priming kinetics with the majority of priming
corresponding with viral replication. This delayed priming
suggests several possible mechanisms. Priming may occur after
4 hours simply because input virus was not able to stimulate
activation, and viral replication was necessary either to increase
the amount of stimuli or to produce stimuli in a recognized
structure. Another hypothesis for the late priming is that it occurs
as a result of increased expression of IFN-responsive genes. One of
the most likely proteins to account for cDC priming would be
RIG-I, which is necessary for DC activation to influenza viruses
[7]. The significance of crucial IFN-responsive genes acting as
viral sensors, rather than other proteins involved in DC activation,
like IRFs, is that IFN does not prime cDCs responses to TLR
ligands (Table 1). This supports the notion that IFN priming in
cDCs is augmenting the internal pathway of activation, most likely
mediated by RIG-I. However, these two hypotheses of cDC
priming are not mutually exclusive; and we propose that both may
occur simultaneously. IFN priming in cDCs is dependent on viral
replication being sensed by the RLR pathway and due to the
increased expression of IFN-responsive genes like RIG-I, this
internal pathway is able to stimulate a stronger cDC activation
profile.
In contrast to the delayed cDC priming, pDCs demonstrate
priming most substantially at 4 hours post infection and priming
decreases with time. Again differing from cDCs, pDC activation
did not follow the viral replication time course, suggesting a very
different mechanism of priming than in cDCs. This finding is
consistent with the profile of pDC activation by viruses being
predominantly TLR dependent. In our experiments IFN-b
priming in pDC was independent of viral replication and seen
with both live virus and TLR ligand activation (Figures 3–6, and
Table 1, bottom part). These results suggest that although IFN-b
treatment did not enhance the TLR pathway in cDCs, IFN-b can
enhance the overall activation within cells that utilize the TLR
pathway as its primary viral sensor.
Lastly, the results from both pDCs and cDCs with IFN-b added
post infection, demonstrate that while priming occurs over a broad
time range, there is a point where the virus ‘wins’ and the
enhancing effects of IFN-b treatment are not able to supplement
the DC activation. It is possible that the viral sensors are made too
late to be useful or they may not be made at all due to the
inhibition of cellular machinery by the virus.
Figure 7. IFN priming allows cDCs to partially overcome inhibition by IFN antagonist protein of the influenza virus. cDCs were either
infected with PR8 virus (PR8) or PR8 virus lacking the NS1 protein (DNS1) or left non-infected (NI). NI and PR8 samples were also pretreated with IFN-b
(50, 500, 5,000 units/ml) for 3 hours prior to the infection. Infection was stopped after 6 hours and mRNA expression patterns were determined for
genes labeled. Mean of samples are depicted with error bars of the standard deviation of each sample. Data are representative of at least three
independent experiments.
doi:10.1371/journal.ppat.1000193.g007
IFN-b Enhancement of Human DC Activation
PLoS Pathogens | www.plospathogens.org 9 October 2008 | Volume 4 | Issue 10 | e1000193In summary, type I IFN priming overrides the inhibitory effects
of viral antagonists on DC activation by eliciting strong responses
in cDCs and even stronger responses in pDCs. The significance of
this finding suggests the importance of evaluating DC responses in
an environment similar to that in vivo. As DCs in vivo are
responding to viruses in the context of setting that may contain
multiple pro-inflammatory cytokines and chemokines, the effects
of this environment cannot be disregarded. When evaluating a DC
response, it is important to consider the actual stimuli the cells may
have been exposed to prior to viral infection. Moreover, here we
show that the establishment of antiviral state by type I IFN does
not inhibit DC activation but rather, exerts priming effects,
allowing for a more efficient detection and stronger response. Our
data have important implications for the understanding of the
initiation of immunity in the infected host, since differences in the
micro-environment of the infected DC may account for different
outcomes in adaptive immunity.
Materials and Methods
Viruses and cells
Influenza virus PR8 (H1N1) was grown in 9-day-old embryo-
nated chicken eggs (SPAFAS; Charles River Laboratories). PR8
was titrated on MDCK cells by detection of hemagglutination
(HA) activity in the supernatants after 48 h of infection, as
previously described and by immunoflourescence, using a
monoclonal antibody, PY102, specific for the HA protein
(obtained from Jerome L. Schulman). All virus infections were
performed in infection medium (Dulbecco’s modified Eagle’s
medium, 0.35% bovine serum albumin, 0.12% NaHCO3,
100 mg/ml penicillin-streptomycin). For influenza virus titrations,
2.5 mg/ml trypsin was included in the infection medium.
MDCK and Vero cells were grown in tissue culture medium
(Dulbecco’s modified Eagle’s medium [Invitrogen] with 10% fetal
calf serum [HyClone], 1 mM sodium pyruvate [Invitrogen],
2m M L-glutamine [Invitrogen], and 50 mg/ml gentamicin
[Invitrogen]). All cells were grown at 37uCi n7 %C O 2.
Isolation and culture of human DCs
Peripheral blood mononuclear cells were isolated by Ficoll
density gradient centrifugation (Histopaque; Sigma Aldrich) from
buffy coats of healthy human donors (Mount Sinai Blood Donor
Center and New York Blood Center). CD14+ cells were
immunomagnetically purified using anti-human CD14 antibody-
labeled magnetic beads and BDCA4+ cells were immunomagne-
tically purified using anti-human BDCA4 (CD304)
+ antibody-
labeled magnetic beads and iron-based Midimacs LS columns
(Miltenyi Biotec). After elution from the columns, CD14+ cells
were plated (0.7610
6 cells/ml) in DC medium (RPMI [Invitro-
gen], 10% fetal calf serum [HyClone] or 4% human serum
[Cambrex], 100 units/ml of penicillin, and 100 mg/ml strepto-
mycin [Invitrogen]) supplemented with 500 U/ml human gran-
ulocyte-macrophage colony-stimulating factor (GM-CSF; Pepro-
tech) and 1,000 U/ml human interleukin-4 (IL-4; Peprotech) and
incubated for 5 to 6 days at 37uC. Our cultured DCs were
routinely 95–98% positive for CD11c as tested by flow cytometry,
from over 40 independent isolations. BDCA4
+ cells were treated
immediately following elution. PDCs were tested for purity by flow
cytometry. Briefly, BDCA4
+ cells were stained with fluorescein
isothiocyanate FITC)-linked CD123 and phycoerythrin (PE)-
linked BDCA2 (CD303), according to the manufacturer’s
instructions (Miltenyi Biotec), and the expression of each marker
was determined by flow cytometry using an FC500 flow cytometer
from Beckman Coulter. Data were analyzed using Flowjo
software. The average purity of BDCA4+ cells was
91.0765.01% as defined as double positive for CD123 and
BDCA2 (CD303) with n=63. Each experiment used an
independent donor with no overlap between pDC and cDC
donors.
Infection and treatment of DCs
Immediately following isolation for BDCA4+ cells and after 5 to
6 days in culture for the CD14+ cells, DCs were either pre-treated
with 5 to 5,000 U/ml IFN- b (PBL) and/or were treated with one
of the following: live influenza PR8 virus at a multiplicity of
infection (MOI) of 0.5, UV-inactivated influenza virus at a
MOI=5, 500 ng/ml LPS (Sigma-Aldrich), 6 ug/ml CpG (Coley
Pharmaceutical Group), 2.5 ug/ml poly (I:C) (InvivoGen), 0.5 ug/
ml CL-075 (InvivoGen), 1 ug/ml Gardiquimod (InvivoGen). Cells
were treated in medium (RPMI [Invitrogen], 4% human serum
[Cambrex], 100 units/ml of penicillin, and 100 mg/ml strepto-
mycin [Invitrogen]) at 1610
6 cells/ml for different time periods,
depending on the experiment. In experiments in which the IFN
media was removed, fresh media was added prior to viral
infection.
Capture ELISAs
Capture enzyme-linked immunosorbent assays (ELISAs) for
IFN-a, TNF-a, IL-6, IL-8, RANTES, IP-10 and MIP1-b
(Upstate/Millipore) were performed as part of a multiplex assay
following the manufacturer’s protocol. Plates were read in a
Luminex plate reader, and data were analyzed using software from
Applied Cytometry Systems. All samples were assayed in duplicate
or triplicate.
RNA extraction from human DCs
Samples of 0.15610
6 to 0.5610
6 DCs differentially treated
according to the experimental protocol were pelleted, and RNA
was isolated and treated with DNase by using an Absolutely RNA
RT-PCR micro prep kit (Stratagene). RNA was quantified using a
Nanodrop spectrophotometer (Nanodrop Technologies).
Quantitative real-time PCR
qRT-PCR of the extracted RNAs was performed by using a
previously published SYBR green protocol with an ABI7900 HT
thermal cycler by the Mount Sinai Quantitative PCR Shared
Research Facility. Each transcript in each sample was assayed in
triplicate, and the mean cycle threshold was used to calculate the
x-fold change and control changes for each gene. Three
housekeeping genes were used for global normalization in each
experiment (actin, Rps11, and tubulin genes). Data validity by
modeling of reaction efficiencies and analysis of measurement
precision was determined as described previously [17].
Statistical Analyses
Statistical analyses were performed using student’s two-tailed t
test. Unless otherwise indicated, means6standard deviation for
each sample are shown.
Supporting Information
Figure S1 IFN-b priming seen in pDCs response to TLR7
ligand. pDCs were pretreated with IFN-b (50 units/ml) for
3 hours. Following pretreatment, the IFN media was removed
and cells were treated with Gardiquimod (IFN+Gard) for 3 hours.
Control pDCs were either treated with Gardiquimod only (Gard),
pretreated with IFN only (IFN), or neither (NI). (A) Copy number
of mRNA expression values are depicted for the specific gene
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Mean of samples are depicted with error bars of the standard
deviation of each sample. Data is representative of at least three
independent experiments. All samples have student t test p,0.05
between the IFN+PR8 condition and the other conditions, with
the exception of IL-6 mRNA expression.
Found at: doi:10.1371/journal.ppat.1000193.s001 (0.79 MB TIF)
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